Janux Therapeutics (JANX) to Release Earnings on Wednesday

Janux Therapeutics (NASDAQ:JANX) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Janux Therapeutics to post earnings of ($0.60) per share and revenue of $3.0710 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 6:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Price Performance

Shares of JANX opened at $28.71 on Monday. Janux Therapeutics has a 1-year low of $21.73 and a 1-year high of $71.71. The stock has a market cap of $1.73 billion, a PE ratio of -15.95 and a beta of 2.83. The firm has a 50-day simple moving average of $24.68 and a two-hundred day simple moving average of $25.29.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total value of $500,949.90. Following the completion of the transaction, the insider owned 82,139 shares in the company, valued at approximately $2,469,098.34. The trade was a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in JANX. Osaic Holdings Inc. lifted its stake in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Janux Therapeutics by 185.1% in the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after acquiring an additional 4,982 shares during the last quarter. American Century Companies Inc. purchased a new position in Janux Therapeutics in the second quarter worth approximately $261,000. Finally, AQR Capital Management LLC lifted its stake in Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after acquiring an additional 4,059 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JANX. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Truist Financial began coverage on shares of Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target for the company. Guggenheim began coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 price target for the company. Finally, Barclays assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, September 17th. They set an “overweight” rating and a $47.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $79.08.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.